Has Jie Tang, MD received payments from drug or device companies?

Yes. Drug and device makers reported $22,666 in general payments to Jie Tang, MD across 67 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jie Tang, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jie Tang, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jie Tang, MD

Nephrology · Riverside, RINPI 1871583997

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $14,640 of the $22,666 with a category attached, or 64.6%. 16 manufacturers reported payments, led by Alnylam Pharmaceuticals Inc. at 38.5% of the total. Among nephrology clinicians in RI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$22,666in general payments, 2019–2025

Across 67 payments — averaging $338.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Alnylam Pharmaceuticals Inc.$9K
Travere Therapeutics, Inc.$6K
Calliditas Therapeutics US Inc.$5K
AstraZeneca$824
Bayer$528
Apellis Pharmaceuticals, Inc.$345
plus $1K from 10 others

$150,433in research payments, 2019–2025

Across 2 payments — averaging $75,217 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Vertex$150K

What the payments were for

Consulting fees$14,64065%
Travel & lodging$3,18514%
Food & beverage$4,82421%
Education$170%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Alnylam Pharmaceuticals Inc.	10	$8,716
Travere Therapeutics, Inc.	14	$5,899
Calliditas Therapeutics US Inc.	11	$5,272
AstraZeneca(2 entities)	10	$824
Bayer	6	$528
Apellis Pharmaceuticals, Inc.	2	$345
Akebia Therapeutics Inc	2	$247
Otsuka America Pharmaceutical, Inc.	2	$139
GSK	1	$123
E.r. Squibb & Sons, L.L.C.	1	$121
Ultragenyx Pharmaceutical Inc.	1	$104
Amgen	1	$104
Fresenius USA Marketing, Inc.	3	$94
Nxstage Medical, Inc.	1	$80
Vertex	1	$53
Baxter Healthcare	1	$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

TARPEYO$5,081
Kerendia$465
Empaveli$345
Vafseo$247
LOKELMA$125
AURYXIA$125
BENLYSTA$123
Pomalyst$121
ULTOMIRIS$117
CRYSVITA$104
Parsabiv$104

How this compares

$22,666 in reported general payments places this provider in the 90th percentile of 45 nephrology providers in Rhode Island.

See all nephrology providers in Rhode Island →

Medicare billing

Part B allowed, 2024

$72,863

Medicare patients

179

Services billed

502

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Potassium Citrate ErPotassium Citrate	32	$3,890
Sevelamer Carbonate	22	$2,781
Calcium Acetate	14	$1,287
Losartan Potassium	36	$533
Chlorthalidone	28	$399
Carvedilol	29	$332
Doxazosin Mesylate	14	$250
Torsemide	12	$249
Amlodipine Besylate	33	$236
Furosemide	16	$187
Spironolactone	20	$151
Tamsulosin Hcl	12	$60
Hydrochlorothiazide	12	$40

Paid to pharmacies, not to this prescriber.

Other nephrology in Riverside

Reginald GohhRiverside$47K
Ankur ShahRiverside$27K
Douglas SheminRiverside$22K
Kristen TillquistRiverside$2K
Basma MerhiRiverside$2K
John ObellRiverside$2K
Sandipan ShringiRiverside$1K
George BaylissRiverside$246
Susie HuRiverside$205
Matthew LynchRiverside$180

See the full list for Rhode Island →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →